Join
Live feed
·
PRReleasevia Quantisnow
Alumis Inc. logo
ACELYRIN INC. logo

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

ByQuantisnow·Wall Street's wire, on your screen.
ALMS· Alumis Inc.SLRN· ACELYRIN INC.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALMS (Alumis Inc.), SLRN (ACELYRIN INC.) and more on Quantisnow.

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases | Quantisnow